Abstract: Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) cryoprotectant: the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol, and ethylene glycol; (3) a saline buffer; wherein the salt buffer is a solution containing Na+, K+, Mg+, Cl?, and CH3COO? ions; (4) a vitamin; and (5) an amino acid, wherein the human albumin concentration is 1%-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used or conventional adherent and suspension cells.

Abstract: In one embodiment, an apparatus includes a connecting member configured for positioning on an upper surface of an integrated circuit package and a cable comprising a first end attached to the connecting member and a second end configured for electrically coupling with a power supply component. The connecting member is operable to position the cable for connection to the upper surface of the integrated circuit package to deliver power from the power supply component to the integrated circuit package with the power supply component and the integrated circuit package mounted on an upper surface of a printed circuit board. A method is also disclosed herein.

Abstract: An anomaly prediction tool is employed on a communication network to monitor systems and/or devices on the network for anomalous behaviors. The anomaly prediction tool can include a machine learning (ML) model to detect anomalous network systems operating on the network based on a data tree derived from network configuration data for the network. In some examples, the ML model is a graph-based convolutional neural network.

Abstract: A process for joining polymer molded parts. Providing a first part made from a first material and a second part made from a same or different first material. Attaching an infrared or other thermal bonding material to at least one of the parts in a place for the parts to be joined. Thereafter, heating the at least on infrared bonding material with an infrared heating element and pressing the first part into contact with the second part wherein a bond is formed.

Abstract: Provided are methods for isolating T-cells with T cell receptors (TCRs) optimized for reactivity to specific peptides and decreased cross-reactivity to non-target peptides. Advantageously, TCRs of the invention can be optimized to target cancer antigens and peptides while having reducing reactivity to healthy cells. Methods of the invention utilize a novel combination of culturing conditions that increase T-cell activation and allow for validation of TCR activity. Culturing conditions of the invention further reduce culturing times generally needed to achieve expanded reactive T-cells. Because of the robust nature of the activation and validation conditions of the present invention, variants of identified TCRs can also be optimized and validated for their response to peptides, including cancer peptides.

Abstract: Provided are methods for isolating T-cells with T cell receptors (TCRs) optimized for reactivity to specific peptides and decreased cross-reactivity to non-target peptides. Advantageously, TCRs of the invention can be optimized to target cancer antigens and peptides while having reducing reactivity to healthy cells. Methods of the invention utilize a novel combination of culturing conditions that increase T-cell activation and allow for validation of TCR activity. Culturing conditions of the invention further reduce culturing times generally needed to achieve expanded reactive T-cells. Because of the robust nature of the activation and validation conditions of the present invention, variants of identified TCRs can also be optimized and validated for their response to peptides, including cancer peptides.

Abstract: Described herein are single chain trimer (SCT) polypeptides comprising or consisting essentially of a target peptide, a first linker, at least a portion of a beta-2 microglobulin domain, a second linker, and at least a portion of a major histocompatibility complex (MHC) I alpha chain, or pharmaceutically acceptable derivatives thereof. The SCT polypeptides may further include a leader peptide, e.g., a PHO5, SUC2, app8, or HLA A2 leader sequence at the N-terminus of the target peptide. Further described herein are polypeptide compositions comprising or consisting essentially of a first polypeptide comprising a target peptide, and a second polypeptide comprising at least a portion of a beta-2 microglobulin domain, a second linker, and at least a portion of a major histocompatibility complex (MHC) I alpha chain, a third linker, and a tether peptide, or pharmaceutically acceptable derivatives thereof. The first polypeptide and/or the second polypeptide may further include a leader peptide, e.g.

Abstract: Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) cryoprotectant: the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol, and ethylene glycol; (3) a saline buffer; wherein the salt buffer is a solution containing Na+, K+, Mg+, Cl?, and CH3COO? ions; (4) a vitamin; and (5) an amino acid, wherein the human albumin concentration is 1%-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used or conventional adherent and suspension cells.

Abstract: A process for joining polymer molded parts. Providing a first part made from a first material and a second part made from a same or different first material. Attaching an infrared or other thermal bonding material to at least one of the parts in a place for the parts to be joined. Thereafter, heating the at least on infrared bonding material with an infrared heating element and pressing the first part into contact with the second part wherein a bond is formed.

Abstract: In one embodiment, an apparatus includes a connecting member configured for positioning on an upper surface of an integrated circuit package and a cable comprising a first end attached to the connecting member and a second end configured for electrically coupling with a power supply component. The connecting member is operable to position the cable for connection to the upper surface of the integrated circuit package to deliver power from the power supply component to the integrated circuit package with the power supply component and the integrated circuit package mounted on an upper surface of a printed circuit board. A method is also disclosed herein.

Abstract: Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) cryoprotectant: the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol, and ethylene glycol; (3) a saline buffer; wherein the salt buffer is a solution containing Na+, K+, Mg+, Cl?, and CH3COO? ions; (4) a vitamin; and (5) an amino acid, wherein the human albumin concentration is 1%-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used or conventional adherent and suspension cells.

Abstract: Disclosed herein are system, method, and computer program product embodiments for detecting duplicates with exact and fuzzy matching on encrypted match indexes using an encryption key in a cloud computing platform. An embodiment operates by determining a match rule index value upon reception of a new record. The embodiment encrypts the match index rule value using the customer's encryption key and a deterministic encryption method and stores the encrypted match rule index value. Duplicate detection may be later performed by using the same deterministic encryption method to determine a cypher text for a candidate entry and comparing the ciphertext to the stored encrypted match indexes.

Abstract: Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) cryoprotectant: the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol, and ethylene glycol; (3) a saline buffer; wherein the salt buffer is a solution containing Na+, K+, Mg+, Cl?, and CH3COO? ions; (4) a vitamin; and (5) an amino acid, wherein the human albumin concentration is 1%-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used or conventional adherent and suspension cells.

Abstract: In a method for superimposed conveyance of data and electrical power, a first switch can cycle to convey the electric power and data from a first device. Binary digits of the data from the first device can be represented by transitions, of a voltage at a node of a second device, between a first voltage and a second voltage. A second switch can cycle to convey data from the second device. Binary digits of the data from the second device can be represented by transitions, of a current through a component of the first device, between being less than a threshold and being greater than the threshold. A voltage regulator of the second device can provide, in response to the voltage at the node being within a range of voltages that includes the first voltage and the second voltage, the electrical power to one or more components.

Abstract: A metamaterial-based phase shifting element utilizes a variable capacitor (varicap) to control the effective capacitance of a metamaterial structure in order to control the phase of a radio frequency output signal generated by the metamaterial structure. The metamaterial structure is configured to resonate at the same radio wave frequency as an incident input signal (radiation), whereby the metamaterial structure emits the output signal by way of controlled scattering the input signal. A variable capacitance applied on metamaterial structure by the varicap is adjustable by way of a control voltage, whereby the output phase is adjusted by way of adjusting the control voltage. The metamaterial structure is constructed using inexpensive metal film or PCB fabrication technology including an upper metal “island” structure, a lower metal backplane layer, and a dielectric layer sandwiched therebetween.

Abstract: A neuromodulation device includes electrically conductive coils arranged in an array and circuitry coupled to energize the coils in the array using current pulses that generate an electromagnetic field. The circuitry is configured to control one or more parameters of the current pulses, including at least amplitude and phase of the current pulses, such that the electromagnetic field undergoes constructive and destructive interference that focuses and/or steers a magnetic flux density within a region of interest of a patient.

Abstract: A metamaterials-enhanced solar receiver for a Concentrating Solar Power (CSP) plant includes spectrally-selective metamaterials-enhanced surface features engineered into the sunlight-receiving (upward-facing) surface of a high melting point sunlight absorbing material. The spectrally-selective features include substantially cube-shaped microcavities surrounded by associated interlaced walls disposed in a periodic (waffle-like) array having a grating period in the range of 0.5 to 2 microns, thereby forming a metamaterial structure exhibiting high absorptance efficiency (i.e., above 95%) of incident solar radiation having wavelengths in the visible light spectrum through induced coupling of visible light to the interlaced walls by way of generating surface plasmonic waves that resonate at visible light frequencies, whereby thermal energy is efficiently absorbed into the solar receiver to heat a transfer fluid.

Abstract: A light-emitting device is provided. The light-emitting device comprises a substrate; a semiconductor stack on the substrate comprising a first region and a second region; a first trench extending from the semiconductor stack to the substrate to expose a surface of the substrate and separating the first region from the second region; and a first electrode comprising a first pad on the first region and a first extending electrode connecting to the first pad, wherein the first extending electrode is across the first trench.

Abstract: A lightweight deployable antenna assembly for, e.g., microsatellites including multifilar (e.g., quadrifilar) antenna (MHA) structures rigidly maintained in an array pattern by a lightweight linkage and collectively controlled by a central antenna feed circuit and local antenna feed circuits to perform phased array antenna operations. The linkage is preferably an expandable (e.g., flexural-scissor-grid) linkage capable of collapsing into a retracted/stowage state in which the MHA elements are maintained in a closely-spaced (e.g., hexagonal lattice close-packed) configuration optimized for payload storage. To deploy the antenna for operation, the linkage unfolds (expands) such that the MHA elements are moved away from each other and into an evenly spaced (e.g., wide-spaced hexagonal) pattern optimized for phased array operations. The MHA structures utilize modified helical filar elements including metal plated/printed on polymer/plastic beams/ribbons, or thin-walled metal tubes.

Abstract: A passive radiative cooling system in which an ultra-black emitter includes metamaterial nanostructures disposed on the top surface of a metal sheet, and a conduit structure channels the flow of coolant against a bottom surface of the metal sheet. The metamaterial nanostructures (e.g., tapered nanopores) are configured to dissipate heat from the coolant in the form of emitted radiant energy having wavelengths/frequencies that fall within known atmospheric transparency windows (e.g., 8-13 ?m or 16-28 ?m), the emitted radiant energy being transmitted through a reflective layer into cold near-space. The ultra-black emitter is formed using a modified Anodic Aluminum Oxide (AAO) self-assembly technique followed by electroless plating that forms metal-plated tapered nanopores, and the reflective layer includes a distributed Bragg reflector.